Bal Pharma Limited · NSE:BALPHARMA
Bal Pharma — Q1 FY23 Earnings Presentation
34 slides from Bal Pharma's earnings presentation, Sep 6, 2022
Slide 1: Cover letter to stock exchanges under Regulation 30
Bal Pharma Limited To, 06.09.2022 The Manager-Listing National Stock Exchange of India Ltd Mumbai. BSE Limited Mumbai. Dear Sir, Sub : Investor Presentation for Q1 of FY23. REF : Regulation 30 of SEBI(LODR) Regulations,2015. With reference to the above, we are submitting to the exchanges copy of the
Slide 2: Investor Presentation Q1 FY23
Investor Presentation Q1 FY23
Slide 3: Disclaimer
Disclaimer This presentation and the following discussion may contain “forward looking statements” by Bal Pharma Limited (“Bal Pharma” or the Company) that are not historical in nature. These forward looking statements, which may include statements relating to future results of operations, financial
Slide 4: Contents
CONTENTS ▪ About Us ▪ Industry ▪ Integrated Play ▪ Financial Overview ▪ Leadership Team
Slide 5: About Us
ABOUT US COMMITTED TO QUALITY HEALTH CARE
Slide 6: A Leading Pharmaceuticals player focussed on treating lifestyle diseases
5 A Leading Pharmaceuticals player focussed on treating lifestyle diseases Overview Vision ▪ Established in 1992, today the Company ▪ To be a leading global player in the has a presence across more than 80 Healthcare industry with a focus on countries worldwide with strong Pan India innovation, qual
Slide 7: 30 years of Legacy
6 30 years of Legacy Expanded its API’s portfolio to 20+ and FDF’s to 200+ 2021 2011- 2020 1996- 2011 1992- 1996 1992 Growth The company increased its Invest footprints across geography The company started and with expansion and reaching various integrated play, Company is Implement geographies and
Slide 8: Bal Pharma at a Glance
7 Bal Pharma at a Glance First Indian company to be granted COS for First Indian Gliclazide & company to file Largest producer for Bepotastine &exporter of Gliclazide from in US 70:30 India Exports : Domestic API/ 6 370 tonnes 375 + field force Intermediates, and 3,138+ Finished distribution Formula
Slide 9: Our State-of-the-Art Manufacturing facilities
8 Our State-of-the-Art Manufacturing facilities 6 manufacturing facilities- 3 for API’s & Intermediates , 3 for Finished Dosage Formulations (FDF) Unit 1 – Bangalore, Karnataka Unit 2- Bangalore, Karnataka Unit Dosage Capacity Unit 3- Pune, Form Maharashtra Unit 1 FDF 1.2 bn Tablets 240 mn Capsules
Slide 10: Our State-of-the-Art Manufacturing facilities
9 Our State-of-the-Art Manufacturing facilities API- Unit 6 API- Unit 2 Intermediate- Udaipur, Bangalore, Unit 5 Rajasthan Karnataka Sangli, Maharashtra FDF- Unit 1, FDF- Unit 3 FDF- Unit 4 Bangalore, Pune, Rudrapur, Karnataka Maharashtra Uttarakhan d
Slide 11: Diversified Global Markets
10 Diversified Global Markets Diversified across 80+ countries with mix of API’s and FDF’s 63 countries for API (Domestic market 33%, Regulated markets 14 % other semi-regulated markets 53%) 34 countries for FDF (Domestic 30% in other semi- regulated markets 70%) More than Market Presence 80+ countr
Slide 12: Presence across all segments- An Integrated Player
11 Presence across all segments- An Integrated Player API, Finished Dosage Formulations (FDF) and Herbal with widespread market across geographies ▪ API Manufacturer with 22+ Active Molecules. The range of APIs includes Anti-Diabetic, Anti-Histamine, Anti Inflammatory, Diuretic, Acne Treatment, Anti
Slide 13: Product Portfolio
12 Product Portfolio Top Therapeutic Top Therapeutic usage of API Percentage usage of Percentage Formulations 62% Antidiabetic 21% 48% Antihistamine Analgesics and 4% Anti-inflammatory antipyretics 2% 15% Diuretic Antibacterial 1% Acne treatment 8% 1% Cardiology Antipsychotic 6% Antidiabetics 4% Ant
Slide 14: Industry
INDUSTRY
Slide 15: Pharma Industry
14 Pharma Industry Global ▪ While the global pharmaceutical manufacturing market has reached $402 billion in 2020, the US and European markets alone will be worth $635 and $315 billion in sales by 2024, respectively. ▪ Global market is expected to grow at a compound annual growth rate (CAGR) of 11.3
Slide 16: Pharma Industry
15 Pharma Industry Growth Trend in the overall Low Labour Cost helps to contribution of the pharma industry. reduce cost of production and increase margins. Government Support under the Estimated Aatmnirbhar Bharat government is taking Opportunity with 1.27 tr all the efforts to support Indian Pharm
Slide 17: Integrated Play
INTEGRATED PLAY
Slide 18: Investing in Bal Pharma: A play on integration and diversified mix
17 Investing in Bal Pharma: A play on integration and diversified product-client mix Bal Pharma well poised to deliver sustainable growth over long term An Integrated Player with well Export Markets to Domestic markets to Reframing its diversified product portfolio remain key driver drive the next l
Slide 19: Integrated play- Diversified product & Geographic mix
18 Integrated play- Diversified product & Geographic mix Segmental Therapeutical Geographical Customer Mix Mix Mix Mix Intermediates ▪ 22+ Therapeutic areas ▪ Presence across 80+ • Well diversified customer countries mix. ▪ One of the large player in Anti Diabetic Therapeutic ▪ Domestic operations a
Slide 20: Healthy Order Book & Strong Product Pipeline
19 Healthy Order Book & Strong Product Pipeline API (including Intermediates) Formulations (Finished Dosages) Order book of Rs. 370 Mn in API to be Order book of Rs. 270 Mn in FDF to be Order Book (as on executed in next months including both executed in next months including both date) domestic and
Slide 21: Export Markets – a key driver of our current offerings
20 Export Markets – a key driver of our current offerings ▪ Company exports more than 22 API’s ▪ Company exports API’s to 80+ countries ▪ API exports form around ~ 58% in API’s Revenue API ~36% ▪ Competitive Pricing along with qualitative standards has led to repetitive orders of Export Revenue from
Slide 22: Domestic Formulations: Increasing Market presence
21 Domestic Formulations: Increasing Market presence ▪ PAN India Operations Vibrant Multispecialty ▪ 246+ Field Force; 2800+ Stockists ; 41,300+ Doctor Reach ▪ Nutritional supplements; Anti Allergic, Anti- Fungal, Gastro, Gynecological ▪ Presence in 8 states Glyduz and Diabetes and ▪ 127+ Field Forc
Slide 23: Snapshot of Major Domestic Formulation Division
22 Snapshot of Major Domestic Formulation Division Vibrant Lifezen Glyduz and Servetus
Slide 24: Pharmaceutical Production Linked Incentive (PLI) Scheme
23 Pharmaceutical Production Linked Incentive (PLI) Scheme The scheme is aimed towards pushing domestic manufacturing of key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs) to reduce import dependence on such input materials Sector Benefits Sector Beneifts
Slide 25: Financial Overview
FINANCIAL OVERVIEW
Slide 26: Yearly Financial Highlights
25 Yearly Financial Highlights ₹ Mn Reven 2,803 API ue 3,000 2,493 /Formulation 2,500 2,231 70% 60% 57% 57% 60% 53% 2,000 1,707 47% 50% 40% 43% 43% 1,500 40% 30% 1,000 20% 500 10% - 0% FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 API Formulations Export/Domes tic 70% 62% 62% 65% 38% 38% 3… 30% FY19 FY20
Slide 27: Key Result Highlights
26 Key Result Highlights FY22 in Highlights ₹ Mn Reven API/Formulatio ue 2,804 ns 57% 2,493 12% 53% 47% 43% FY21 FY22 FY 21 FY22 API Formulations Domestic/Exp ort 65% 70% 35% 30% FY 21 FY 22 Domestic Export
Slide 28: Key Result Highlights
27 Key Result Highlights Q1FY23 and FY22 in Highlights ₹ Mn Revenu EBITD PA e A T 711 -1.5% 701 76 -21.23% 60 21 -34.50% 14 Q1 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Revenu EBITD PA e A T 12% 2,804 2,493 263 -12% 232 91 -6% 86 FY21 FY22 FY21 FY22 FY21 FY22
Slide 29: Corporate Structure
Corporate 28 Structure Corporate Shareholding Structure Pattern Bal Pharma Limited (Having 5 manufacturing facilities API, Intermediates and FDF Holding Company) Promoter & Promoter Group Golden Drugs Private Limited 48% Public (Unit of API Manufacturing ) 52% 100% Subsidiary Lifezen Health care Pri
Slide 30: GMP Accreditation
29 GMP Accreditation Unit 1 – Bangalore (Karnataka) S. Country Inspection / Accreditation Authority No. 01 Tanzania Tanzania Medicines & Medical Devices Authority (TMDA ) 02 Philippines Philippines Food and Drug Administration (PFDA) 03 Yemen Supreme Board for Medicine & Medical Appliances 04 Kenya
Slide 31: Leadership Team
= < Lu - o <= ” o Lu Q < Lu =
Slide 32: Meet the Board
31 Meet the Board He is a chief promoter and Managing Director of the Company and with over 30 years of Shailesh Siroya pharmaceutical industry experience . He is an Managing Director MBA ( Finance ) Graduate from Akron University, Ohio, USA and is heading the management team of the Company since it
Slide 33: Meet the Board
32 Meet the Board Dr. C.V Srinivas is a Fellow in otology from Dr. C V Srinivas Andre Sulta, Paris, France and did MS from Jatish Seth He is an Independent, non-executive Director of the Company with pharma experience of Independent K.G Institute of Medical Sciences and Independent over 30 years . H
Slide 34: Thank You!
Mr. Shailesh Siroya Managing Director Email- shailesh@balpharma.com Mr. Bharath Bhushan D V M&A and Investor Relations THANK YOU! Email- bharathbhushan@balpharma.com www.balpharma.com Mr. Chintan Mehta Ms. Sonam Raghuvanshi Email- bal.pharma@dickensonworld.com IR Consultants – Dickenson World